Patents by Inventor Grigori Ermakov

Grigori Ermakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
    Patent number: 11773150
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: October 3, 2023
    Assignees: Merck Sharp & Dohme LLC, Ambrx, Inc.
    Inventors: Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS
    Publication number: 20200392197
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Applicants: Merck Sharp & Dohme Corp., Ambrx, Inc.
    Inventors: Paul E. Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
    Patent number: 10800826
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 13, 2020
    Assignees: Merck Sharp & Dohme Corp., Ambryx, Inc.
    Inventors: Paul Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan
  • ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS
    Publication number: 20190071483
    Abstract: Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: October 4, 2016
    Publication date: March 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Carrington, Grigori Ermakov, Robert M. Garbaccio, Wolfgang Seghezzi, Elisabetta Bianchi, Federica Orvieto, Dennis Gately, Nick Knudsen, Anthony Manibusan